摘要
There are many self evident truths when it comes to genetic testing in epilepsies:classifying epilepsy and idenifying the co-morbidities helps you pick the right panel;sending the test increases your chance of making that diagnosis;increased panel testing broadens the phenotype.The series of children with chromodomain helicase DNA-binding protein 2(CHD2)variants reported by Feng et al.1 are notable for a number of important reasons,including confirmation of another CHD2 family.
